Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CDC42 | P60953 | 1/20 | 0.50 |
| ▸ | RAC1 | P63000 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.50 |
| ▸ | ACP3 | P15309 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17295985 | 1.00 | LDHA (0.52) | LDHAAKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL17295989 | 1.00 | LDHA (0.52) | LDHAAKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL9768743 | 0.86 | MEN1 (0.50) | LDHAAKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL27634107 | 0.85 | CA1 (0.47) | LDHAAKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL29716674 | 0.84 | CES2 (0.47) | LDHACYP1A2CA1CA2ACP3 | |
| SCHEMBL5041222 | 0.84 | AKR1C3 (0.69) | AKR1C3AKR1C2PTGS2PTGS1CYP1A2 | |
| SCHEMBL24328881 | 0.83 | PTGS2 (0.50) | LDHAAKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL4709268 | 0.83 | MAPK1 (0.52) | LDHAAKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL5038009 | 0.83 | ACACB (0.53) | PTGS1 | |
| SCHEMBL2387999 | 0.83 | KMT2A (0.55) | AKR1C3AKR1C2PTGS2PTGS1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117964633-B | Preparation method of glabridin | 深圳创元生物医药科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-117964633-B | Preparation method of glabridin | 深圳创元生物医药科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-117964633-A | Preparation method of glabridin | 深圳创元生物医药科技有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117964633-A | Preparation method of glabridin | 深圳创元生物医药科技有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-108349967-B | 1,3, 4-thiadiazole compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2022-02-15 | — | — | CN | disclosed |
| EP-3383871-B1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2019-09-11 | — | — | EP | disclosed |
| EP-3383871-B1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2019-09-11 | — | — | EP | disclosed |
| US-20190119200-A1 | TERTIARY AMIDES AND METHOD OF USE | ABBVIE PHARMACEUTICAL TRADING (SHANGHAI) CO., LTD. (CN) | 2019-04-25 | — | — | US | disclosed |
| EP-3383871-A1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2018-10-10 | — | — | EP | disclosed |
| US-9938265-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2018-04-10 | — | — | US | disclosed |
| CN-101450950-A | Tetracyclic heterocompounds as estrogen receptor modulators | ORTHO MCNEIL PHARM INC (US) | 2009-06-10 | — | — | CN | disclosed |
| WO-2008046527-A1 | ACYLAMINOPYRAZOLES FOR TREATING CARDIOVASCULAR DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008046527-A1 | ACYLAMINOPYRAZOLES FOR TREATING CARDIOVASCULAR DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-04-24 | — | — | WO | disclosed |
| CN-1745085-A | Novel tetracyclic heteroatom containing derivatives as selective estrogen receptor modulators | ORTHO MCNEIL PHARM INC (US) | 2006-03-08 | — | — | CN | disclosed |
| US-5756504-A | TREATMENT OF DYSMENORRHEA, PREVENTION OF PREMATURE LABOR | MERCK & CO., INC. (US) | 1998-05-26 | — | — | US | disclosed |
| EP-0751773-A4 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1997-07-16 | — | — | EP | disclosed |
| EP-0751773-A1 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1997-01-08 | — | — | EP | disclosed |
| US-5464788-A | Stopping labor | MERCK & CO., INC. (US) | 1995-11-07 | — | — | US | disclosed |
| WO-1995025443-A1 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-09-28 | — | — | WO | disclosed |
| US-4493823-A | USING CARBOXYBENZENE COMPOUND | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1985-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119200-A1 | TERTIARY AMIDES AND METHOD OF USE | LPAR1, LPAR3, LPAR2 | LDHA 2046/4885AKR1C3 327/4885AKR1C2 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.